Dark

Check out our Dark Pool Levels

THR
THERMON GROUP HOLDINGS, INC.
stock NYSE

Inactive

May 29, 2026

61.14USD-8.487%(-5.67)2,871,549

Pre-market

0.00USD-100.000%(-66.81)0

After-hours

0.00USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Nov 9, 2021

11:29AM EST Thermon Group Holdings Q2 EPS $0.12 Beats $0.11 Estimate, Sales $81.30M Beat $71.40M Estimate Benzinga

11:29AM EST Thermon Group Holdings Sees FY22 Sales $330M-$345M Vs. $303.53M Est. Benzinga

11:25AM EST Earnings Scheduled For November 9, 2021 Benzinga

Nov 8, 2021

09:59AM EST Thermon Group Holdings's Earnings Outlook Benzinga

Nov 5, 2021

12:51PM EDT Thermon Group Holdings's Debt Overview Benzinga

Sep 30, 2021

01:00AM EDT Decision taken to move the highest dose of THR-149 (0.13mg) into Part B of the study based on favorable safety profile and positive efficacy data GlobeNewswire Inc

Sep 9, 2021

01:00PM EDT Oxurion NV Business & Financial Update H1 2021 GlobeNewswire Inc

Sep 8, 2021

02:00AM EDT OXURION to Present Clinical and Pre-Clinical Data at Upcoming GlobeNewswire Inc

Aug 17, 2021

02:00AM EDT THR-687 is a potent pan-RGD integrin antagonist holding potential as next generation first line therapy for DME, wet AMD and RVO GlobeNewswire Inc

Aug 16, 2021

02:00AM EDT THR-149 and THR-687 show targeted activity in the eyefollowing intravitreal injection with low systemic exposure GlobeNewswire Inc

Aug 9, 2021

07:43AM EDT Rosenblatt Maintains Buy on Thermon Group Holdings, Raises Price Target to $26 Benzinga

Aug 5, 2021

08:00AM EDT Thermon Group Sees FY22 Sales $293M-$308M Vs. $291.48M Est. Benzinga

07:59AM EDT Thermon Group Holdings Q1 EPS $0.07 Beats $0.03 Estimate, Sales $71.20M Beat $59.56M Estimate Benzinga

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Jun 25, 2021

01:00AM EDT Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149 GlobeNewswire Inc

Jun 16, 2021

09:58AM EDT Looking Into Thermon Group Holdings's Return On Capital Employed Benzinga

Jun 10, 2021

01:00AM EDT THR-687 isa potent pan-RGD integrin antagonistholding potentialas next generation first line therapy for DME GlobeNewswire Inc

Jun 8, 2021

01:00AM EDT THR-149 is a potent plasma kallikrein inhibitor for the treatment of DME in the roughly 40% of the patient population respondingsuboptimally to anti-VEGF therapy GlobeNewswire Inc

May 28, 2021

10:30AM EDT How Does Thermon Group's Debt Look? Benzinga

May 27, 2021

07:52AM EDT Recap: Thermon Group Q4 Earnings Benzinga

07:44AM EDT Thermon Sees FY22 Sales $278M-$295M vs $292.33M Benzinga

07:43AM EDT Thermon Group Holdings Q4 Adj. EPS $0.03 Misses $0.19 Estimate, Sales $73.30M Beat $72.35M Estimate Benzinga

04:29AM EDT Earnings Scheduled For May 27, 2021 Benzinga

May 26, 2021

10:40AM EDT Thermon Group Holdings's Earnings Outlook Benzinga

May 17, 2021

01:30AM EDT OXURION NV Appoints Tom Graney, CFA as Chief Executive Officer GlobeNewswire Inc

Apr 30, 2021

01:30AM EDT OXURION NV Presenting Scientific Data at ARVO 2021 Annual Meeting GlobeNewswire Inc

Apr 13, 2021

01:30AM EDT OXURION NV to Present at Wet AMD and DME Drug Development Summit GlobeNewswire Inc

Apr 12, 2021

01:30AM EDT Oncurious NV Reports Encouraging Data from Phase 1 Dose Escalation GlobeNewswire Inc

Apr 9, 2021

01:38AM EDT -- Oral presentation of Phase 1 dose escalation study of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma (MB) -- Poster presentation of research findings of best therapeutic approach to target CCR8 expressed on tumor regulatory T cells to boost anti-tumor immune responses GlobeNewswire Inc

Apr 7, 2021

11:45AM EDT Oxurion is a leader in the development of pan-RGD integrin antagonists for retinal vascular disorders - THR-687 on track to enter Phase 2 development by mid-year GlobeNewswire Inc

Apr 6, 2021

01:30AM EDT Leuven, BE, Boston, MA, US April 6, 2021 7.30 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care back of the eye therapies, today announces that is has agreed to a capital commitment of up to 30 Million with Negma Group. GlobeNewswire Inc

Apr 5, 2021

08:35AM EDT Global Metals & Mining Investor Conference Presentations Now Available for PR Newswire

Mar 31, 2021

01:30AM EDT Leuven, BE, Boston, MA, US March 31st, 2021 07.30 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, today announces its management will participate and meet one on one with investors at the following upcoming virtual meetings: GlobeNewswire Inc

Mar 24, 2021

08:35AM EDT Global Metals & Mining Live Virtual Investor Conference March 30th & 31st: PR Newswire

Mar 17, 2021

03:00PM EDT Advancing Clinical Development of Next Generation Diabetic Macular Edema (DME) Therapies with Novel MoAs Beyond anti-VEGF GlobeNewswire Inc

07:42AM EDT 10 Biggest Price Target Changes For Wednesday Benzinga

07:10AM EDT Rosenblatt Maintains Buy on Thermon Group Holdings, Raises Price Target to $26 Benzinga

Mar 8, 2021

02:00AM EST Leuven, BE, Boston, MA, US March 8, 2021 08.00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, with a clinical stage portfolio in diabetic eye disease, today announces its management will participate and meet with investors at the following upcomingvirtualmeetings in March: GlobeNewswire Inc

Feb 4, 2021

08:35AM EST Earnings Scheduled For February 4, 2021 Benzinga

07:57AM EST Recap: Thermon Group Holdings Q3 Earnings Benzinga

07:28AM EST Thermon Group Holdings Q3 EPS $0.30 Beats $0.24 Estimate, Sales $79.60M Beat $77.04M Estimate Benzinga

Jan 20, 2021

02:00AM EST Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer GlobeNewswire Inc

Nov 9, 2020

08:46AM EST Rosenblatt Maintains Buy on Thermon Group Holdings, Lowers Price Target to $18 Benzinga

01:30AM EST OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices GlobeNewswire Inc

Nov 5, 2020

07:32AM EST Thermon Group Holdings Q2 Adj. EPS $0.12 Beats $0.07 Estimate, Sales $66.40M Miss $69.65M Estimate Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Oct 22, 2020

12:47PM EDT ONCURIOUS I-O Portfolio Directed at Boosting T Cell Influx and GlobeNewswire Inc

Oct 15, 2020

02:00AM EDT Oxurion NV Business Update Q3 2020 GlobeNewswire Inc

Oct 13, 2020

11:45AM EDT Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer GlobeNewswire Inc

Sep 17, 2020

11:45AM EDT Oxurion NV Business Update - H1 2020 GlobeNewswire Inc

Sep 11, 2020

02:15AM EDT Oxurion NV Business Update and First Half 2020 Financial Results to be announced on 17 September GlobeNewswire Inc

Sep 1, 2020

01:00AM EDT Oxurion NV Reports First Patient Dosed in Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME) GlobeNewswire Inc

Aug 6, 2020

10:41AM EDT Thermon Group Holdings Earlier Reported Q1 EPS $(0.11) Beats $(0.12) Estimate, Sales $56.85M Beat $54.60M Estimate Benzinga

Aug 3, 2020

02:00AM EDT Oxurion NV appoints Grace Chang, M.D., Ph.D. as Chief Medical Officer GlobeNewswire Inc

Share